Nexium
page
1
of
1
Drugs giant AstraZeneca posts 37% profit drop
Jan 31, 2013 05:37 EST
Anglo-Swedish pharmaceuticals giant AstraZeneca said Thursday that net profits sank 37 percent last year, hit by the expiry of drug patents and "tough" markets, and warned revenues would fall further in 2013.
AstraZeneca profits dive on patent expiries
Jul 26, 2012 05:39 EDT
Anglo-Swedish pharmaceuticals giant AstraZeneca said Thursday that second-quarter profits sank, hit by the expiry of key drug patents, tough conditions and competition from generic drugmakers.
FDA says ulcer drugs may raise diarrhea risk
Feb 08, 2012 11:37 EST
(Reuters) - Health regulators said ulcer drugs such as AstraZeneca Plc's blockbuster Nexium could increase the risk of clostridium difficile-associated diarrhea (CDAD).
US settlement puts India's Ranbaxy on the ropes
Jan 29, 2012 17:08 EST
Indian drugs giant Ranbaxy faces a tough road ahead after US authorities imposed stiff conditions to settle a long legal battle over manufacturing safety violations at its plants, analysts say.
Three European companies douse hopes for new drugs
Dec 20, 2011 05:24 EST
LONDON/PARIS (Reuters) - Three of Europe's biggest drugmakers -- AstraZeneca <AZN.L>, Novartis <NOVN.VX> and Sanofi <SASY.PA> -- reported product setbacks on Tuesday, underlining the difficulties of developing new medicines to make up for those going off patent.
Breathing exercises may help soothe heartburn
Dec 15, 2011 16:15 EST
NEW YORK (Reuters Health) - People with milder heartburn problems might find some relief from deep breathing exercises, a small clinical trial suggests.
AstraZeneca slashes 1,150 U.S. sales jobs
Dec 07, 2011 14:10 EST
LONDON (Reuters) - AstraZeneca is cutting nearly a quarter of its U.S. sales force in a second wave of redundancies in as many months as it seeks to reduce costs.
Some reflux symptoms hard to treat
Jun 03, 2011 16:15 EDT
NEW YORK (Reuters Health) - Popular drugs for treating acid reflux are more effective at treating some symptoms than others, a new study finds.
Heartburn drugs offer little asthma relief: study
Apr 13, 2011 14:36 EDT
NEW YORK (Reuters Health) - If you have asthma, your doctor might have you on heartburn drugs to ease your wheezing. But that's not necessarily a good idea, according to a fresh look at the medical evidence.
Study questions heartburn drugs for kids
Apr 05, 2011 17:26 EDT
NEW YORK (Reuters Health) - Acid-suppressing drugs like Prilosec and Prevacid may not be much help for infants with troublesome acid reflux, and there's too little evidence that they help older children and teenagers, a new research review concludes.
No fracture warning needed for OTC ulcer drugs: FDA
Mar 25, 2011 10:19 EDT
BANGALORE (Reuters) - Short-term, low-dose use of a popular group of ulcer drugs is unlikely to pose a risk of fractures, the U.S. Food and Drug Administration said on Wednesday.
FDA says high doses of ulcer drug pose bigger fracture
Mar 23, 2011 14:03 EDT
(Reuters) - U.S. health regulators said on Wednesday that patients taking prescription ulcer drugs at high doses or for longer periods may have increased risk of fractures of the hip, wrist and spine.
FDA says stomach acid drugs can lower magnesium
Mar 02, 2011 17:25 EST
WASHINGTON (Reuters) - Prescription ulcer drugs such as AstraZeneca Plc's blockbuster, Nexium, will carry a new warning that long-term use may cause low magnesium levels, U.S. health officials said on Wednesday.
About 20 bidders circle AstraZeneca unit: sources
Feb 23, 2011 11:34 EST
LONDON (Reuters) - About 20 bidders are readying offers for all or parts of Astra Tech, the dental and medical devices unit that AstraZeneca Plc <AZN.L> hopes could fetch $2 billion, people familiar with the matter said.
EU price cuts and U.S. reform weigh on Big Pharma
Jan 26, 2011 19:04 EST
ZURICH (Reuters) - Europe's drive to cut drug prices as well as U.S. healthcare reforms are likely to dampen global pharmaceutical companies' growth outlooks for 2011.
EU price cuts and U.S. reform weigh on Big Pharma
Jan 24, 2011 06:34 EST
ZURICH (Reuters) - Europe's drive to cut drug prices coupled with U.S. healthcare reforms will weigh on global pharmaceutical companies' growth outlooks for 2011.
AstraZeneca responds to FDA on heart drug Brilinta
Jan 21, 2011 04:59 EST
LONDON (Reuters) - AstraZeneca has replied to the Food and Drug Administration queries about its key new heart drug Brilinta and remains confident about a marketing application for the product.
Heartburn drugs linked to increased pneumonia risk
Dec 21, 2010 16:19 EST
NEW YORK (Reuters Health) - People on two types of widely prescribed heartburn medications may have a higher-than-average risk of developing pneumonia, a new research review finds.
EU steps up generic pharma anti-trust probe
Dec 03, 2010 13:53 EST
Europe stepped up action against drug companies snarling up the entry of cheaper generic medicines onto markets, announcing Friday spot inspections confirmed by British No.2 AstraZeneca.
Facts from the Wikipedia page:
 | |
| Systematic (IUPAC) name | |
|---|---|
| (S)-5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl) methylsulfinyl]-3H-benzoimidazole | |
| Identifiers | |
| CAS number | 119141-88-7 |
| ATC code | A02BC05 |
| PubChem | 4594 |
| DrugBank | APRD00363 |
| ChemSpider | 7843322 |
| Chemical data | |
| Formula | C17H19N3O3S |
| Mol. mass | 345.417 g/mol |
| SMILES | eMolecules & PubChem |
| Pharmacokinetic data | |
| Bioavailability | 50 to 90% |
| Metabolism | Hepatic (CYP2C19, CYP3A4) |
| Half life | 1–1.5 hours |
| Excretion | 80% Renal 20% Faecal |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral, IV
|
